These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 19032457)

  • 121. [Clinical significance of cholangitis].
    CHLUMSKY J
    Cas Lek Cesk; 1960 Jul; 99():952-6. PubMed ID: 13693198
    [No Abstract]   [Full Text] [Related]  

  • 122. [Chronic cholangitis, clinical picture and therapy].
    RYSS SM; SMAGIN VG
    Klin Med (Mosk); 1958 Mar; 36(3):20-7. PubMed ID: 13550615
    [No Abstract]   [Full Text] [Related]  

  • 123. EGFR monoclonal antibody panitumumab inhibits chronic proliferative cholangitis by downregulating EGFR.
    Liu SH; Chen XF; Xie ZB; Zhou J
    Int J Mol Med; 2019 Jul; 44(1):79-88. PubMed ID: 31115490
    [TBL] [Abstract][Full Text] [Related]  

  • 124. Effective Treatment of Chronic Proliferative Cholangitis by Local Gentamicin Infusion in Rabbits.
    Yang Q; Wu Z; Liu F; Wang J; Ma W; Hu H; Li F; Pan Q
    Biomed Res Int; 2018; 2018():6751952. PubMed ID: 30140699
    [TBL] [Abstract][Full Text] [Related]  

  • 125. Treatment of chronic proliferative cholangitis with c-myc shRNA.
    Li FY; Cheng NS; Cheng JQ; Mao H; Jiang LS; Li N; He S
    World J Gastroenterol; 2009 Jan; 15(1):95-101. PubMed ID: 19115473
    [TBL] [Abstract][Full Text] [Related]  

  • 126. Practical value of applying cdc2 kinase shRNA to chronic proliferative cholangitis in treatment of hepatolithiasis.
    Li FY; Cheng NS; Cheng JQ; Mao H; Jiang LS; Li QS; Zhou Y
    Hepatogastroenterology; 2009; 56(94-95):1477-82. PubMed ID: 19950813
    [TBL] [Abstract][Full Text] [Related]  

  • 127. Suppression of proliferative cholangitis by E2F decoy oligodeoxynucleotide.
    Yoshida M; Yamamoto N; Nitta T; Uehara T; Terao R; Hatano E; Iimuro Y; Yamaoka Y
    J Surg Res; 2002 Feb; 102(2):95-101. PubMed ID: 11796004
    [TBL] [Abstract][Full Text] [Related]  

  • 128. Epidermal growth factor receptor as a target for anti-proliferative treatment of proliferative cholangitis in hepatolithiasis.
    Li F; Zhou Y; Cheng N; Mao H; Jiang L; Li N; Li Q; de Jong MC; Pawlik TM
    J Surg Res; 2011 Mar; 166(1):87-94. PubMed ID: 20097367
    [TBL] [Abstract][Full Text] [Related]  

  • 129. Significance of controlling chronic proliferative cholangitis in the treatment of hepatolithiasis.
    Li FY; Cheng NS; Mao H; Jiang LS; Cheng JQ; Li QS; Munireddy S
    World J Surg; 2009 Oct; 33(10):2155-60. PubMed ID: 19641953
    [TBL] [Abstract][Full Text] [Related]  

  • 130. siRNA vs. shRNA: similarities and differences.
    Rao DD; Vorhies JS; Senzer N; Nemunaitis J
    Adv Drug Deliv Rev; 2009 Jul; 61(9):746-59. PubMed ID: 19389436
    [TBL] [Abstract][Full Text] [Related]  

  • 131. Proliferating cell nuclear antigen shRNA treatment attenuates chronic proliferative cholangitis in rats.
    Li FY; Cheng NS; Cheng JQ; Mao H; Zhou Y; Jiang LS; Li N
    J Gastroenterol Hepatol; 2009 May; 24(5):920-6. PubMed ID: 19032457
    [TBL] [Abstract][Full Text] [Related]  

  • 132.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 133.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 134.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 135.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 136.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 137.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 7.